• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Global Bladder Cancer Therapeutics & Diagnostics Market - Expected to Grow 3-5% by 2020 - Research and Markets

    Global Bladder Cancer Therapeutics & Diagnostics Market - Expected to Grow 3-5% by 2020 - Research and Markets

  2. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2016 - Research and Markets

    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2016 - Research and Markets

  3. Global Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Sanofi, Novartis, Bayer - Research and Markets

    Global Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Sanofi, Novartis, Bayer - Research and Markets

  4. Dow futures slide almost 100 points as Brexit fears keep nagging

    Dow futures slide almost 100 points as Brexit fears keep nagging

  5. MARKET SNAPSHOT: Dow Futures Slide Almost 100 Points As Brexit Fears Keep Nagging

    MARKET SNAPSHOT: Dow Futures Slide Almost 100 Points As Brexit Fears Keep Nagging

  6. Sanofi, Pfizer, Celgene may each pursue Medivation takeover

    Sanofi, Pfizer, Celgene may each pursue Medivation takeover

  7. Brexit means little for biotech stocks, analyst says

    Brexit means little for biotech stocks, analyst says

  8. Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

    Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

  9. Will the Election Affect Earnings?

    If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.

  10. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.